Insider Sale at Haemonetics Corp (HAE): EVP, Chief Technology Officer Anila Lingamneni Sells ...
On May 6, 2024, Anila Lingamneni, the Executive Vice President and Chief Technology Officer of Haemonetics Corp (NYSE:HAE), sold 2,305 shares of the company. The transaction was documented in a recent SEC Filing. This sale is part of a series of transactions over the past year, where the insider has sold a total of 6,914 shares.
Haemonetics Corp (NYSE:HAE) specializes in products for blood and plasma collection and processing. The company provides a range of integrated solutions that improve the safety, efficiency, and effectiveness of blood supply chains in healthcare.
On the date of the sale, shares of Haemonetics Corp were priced at $95, resulting in a market cap of approximately $4.74 billion. The price-earnings ratio of the company stood at 37.91, which is above the industry median of 30.22.
According to the GF Value, the intrinsic value estimate for Haemonetics Corp is $93.53 per share, making the stock Fairly Valued with a price-to-GF-Value ratio of 1.02.
The insider transaction history for Haemonetics Corp shows no insider buys over the past year, with a total of 7 insider sells recorded in the same period.
The GF Value is calculated based on historical multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor reflecting past returns and growth, and supplemented by future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
